Anisomycin|22862-76-6|(茴香霉素; Flagecidin; Wuningmeisu C)-陌孚医药/Medlife

您当前的位置：

Anisomycin (Synonyms: 茴香霉素; Flagecidin; Wuningmeisu C)

目录号: PC11804 纯度: ≥98%

CAS No. :22862-76-6

商品编号	规格	价格	会员价
PC11804-10mg	10mg	¥490.00	请登录
PC11804-50mg	50mg	¥980.00	请登录
PC11804-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥490.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Anisomycin

中文别名

茴香霉素;Anisomycin 茴香霉素;茴香霉素(链霉菌属);茴香霉素, 来源于浅灰链霉菌;(2R,3S,4S)-2-(4-甲氧苯基)-3,4-吡咯二醇3-乙酸酯;梧宁霉素 C

英文名称

Anisomycin

英文别名

3,4-Pyrrolidinediol,2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2R,3S,4S)-;Anisomycin;Anisomycin from Streptomyces griseolus;Anisomycin,(2R,3S,4S)-2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol3-acetate;(2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol 3-Acetate;2-p-methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine;ANISOMYCIN,STREPTOMYCES GRISEOLUS;antibioticpa-106;Wuningmeisu C;Flagecidin;(-)-Anisomycin;(2R,3S,4S)-2-(p-Methoxyphenylmethyl)-3-acetoxy-4-hydroxypyrrolidine;NSC 76712;(2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate;NSC76712;(2R,3S,4S)-2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate;Upjohn 204t3;2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate;6C74YM2NGI;MLS001066392;Anisomycin, Streptomyces griseolus;1,4,5-Trideoxy-1,4-imino-5-(p-methoxyphenyl)-D-xylo-pentitol 3-acetate;SMR00047

Cas No.

22862-76-6

分子式

C₁₄H₁₉NO₄

分子量

265.31

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK. Anisomycin is a bacterial antibiotic.

性状

Solid

IC50 & Target[1][2]

JNK	DNA synthesis

体外研究(In Vitro)

To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) .

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Balb/c mice of both sexes (4-5 weeks old)
Dosage:	84, 99, 116, 136 or 160 mg/kg; 0.2 mL per mouse
Administration:	Intravenously injected through mouse tail vein
Result:	The calculated LD₅₀ for Anisomycin was 119.64 mg/kg.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

结构分类

来源

Streptomyces griseolus

参考文献

[1]. Lu Z, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells. [Information]

[2]. Gao X, et al. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium. Cardiovasc Res. 2018 Apr 1;114(5):737-746. [Information]

[3]. Zhengle Tang, et al. In vivo toxicological evaluation of Anisomycin. Toxicol Lett. 2012 Jan 5;208(1):1-11. [Information]

[4]. Synthesis Marina Macías-Silva, et al. Anisomycin is a Multifunctional Drug: More than Just a Tool to Inhibit Protein. Current Chemical Biology, 2010, 4, 124-132.

溶解度数据

体外研究:

DMSO : ≥ 50 mg/mL (188.46 mM)

H₂O : 4 mg/mL (15.08 mM; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7692 mL	18.8459 mL	37.6918 mL
5 mM	0.7538 mL	3.7692 mL	7.5384 mL
10 mM	0.3769 mL	1.8846 mL	3.7692 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (9.42 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.42 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.42 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.42 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.42 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.42 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation